Previous 10 | Next 10 |
Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation: MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, ...
BRISBANE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society of Cardiology Congress 2020 (ESC ...
BRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET. A webcast of the presentation wi...
Image source: The Motley Fool. MyoKardia, Inc. (NASDAQ: MYOK) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading
MyoKardia, Inc. (MYOK) Q2 2020 Earnings Conference Call August 04, 2020, 16:30 ET Company Participants Tassos Gianakakos - President, CEO & Director Jay Edelberg - SVP, Clinical Development William Fairey - Chief Commercial Officer & EVP Taylor Harris - CFO Conferenc...
MyoKardia (NASDAQ: MYOK ) : Q2 GAAP EPS of -$1.27 beats by $0.18 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one of incredible progress across our R&D pipeline, including the exciting new data ...
MyoKardia reports initiating trial for invasive septal reduction therapy MyoKardia Inc. ( MYOK ) announced that it has dosed the first person for the Phase 3 VALOR-HCM clinical trial. The study aims to provide direct clinical evidence of mavacamten’s capability to alleviate the re...
BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey B. Geske, M.D. has changed. The corrected release follows: MyoKardia, Inc. (Nasdaq: MY...
The first patient has been dose d in a Phase 3 clinical, VALOR-HCM , evaluating MyoKardia's ( MYOK -0.5% ) mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options...
News, Short Squeeze, Breakout and More Instantly...
EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten T reatment Resulted in Favorable Effect on Cardiac Structure -- Significantly Reduced Hypertrophy in Patien...
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with ...
BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovas...